GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Allogene Therapeutics
Allogene Therapeutics is a pioneer in allogeneic CAR-T cancer therapy (off-the-shelf cell therapy). Its stock price is a venture bet that its approach will be more scalable and less expensive than existing autologous methods.
Share prices of companies in the market segment - Oncology cell gene therapy
Allogene Therapeutics (ALLO) is a biotech company pioneering the development of allogeneic CAR-T therapy (off-the-shelf cell therapy) for the treatment of cancer. We classify it under the heading "Cell and Gene Therapy." The chart below illustrates the dynamics of this revolutionary biotech sector.
Broad Market Index - GURU.Markets
Allogene Therapeutics is a leading company developing universal ("allogeneic") CAR-T cell therapy for cancer. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Allogene compares to it.
Change in the price of a company, segment, and market as a whole per day
ALLO - Daily change in the company's share price Allogene Therapeutics
Shares of Allogene, a pioneer in allogeneic CAR-T therapy, are extremely volatile. Change_co measures the market reaction to clinical trial data. This metric is an essential component in building valuation models for companies at the forefront of oncology on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Allogene Therapeutics, Inc. is an oncology company. This chart illustrates the extreme volatility of the biotech sector. Comparison with the performance of ALLO, a pioneer in allogeneic cell therapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Allogene is a biopharmaceutical company pioneering the development of "off-the-shelf" (allogeneic) CAR-T therapy for cancer treatment. The cell therapy sector is one of the most advanced and volatile in biotech. The chart below reflects the average daily fluctuations in this industry, serving as a benchmark for evaluating Allogene's highly volatile stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Allogene Therapeutics
Allogene Therapeutics' year-to-date performance is a story of the development of "off-the-shelf" CAR-T cell therapies. Its 12-month market cap depends entirely on clinical trial data. The success of its approach, which does not require the use of the patient's own cells, could fundamentally change the availability and cost of this revolutionary cancer treatment.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of off-the-shelf (allogeneic) CAR-T therapy for cancer treatment. Its stock price reflects the enormous potential of its breakthrough scientific platform and the high risks associated with clinical trials.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Allogene is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's stock chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Allogene Therapeutics
Allogene, a cell therapy company, is a speculative company. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its "off-the-shelf" CAR-T cancer treatments, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Allogene Therapeutics is a pioneer in the development of "allogeneic" CAR-T therapy, which uses donor cells to create versatile cancer treatments. This could make cell therapy more accessible. The chart below reflects the overall sentiment in the gene and cell therapy sector, where Allogene is addressing a key challenge.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Allogene Therapeutics is a biotech company developing allogeneic CAR-T cancer therapy. Its shares are a bet on the success of its scientific platform. Their performance is entirely dependent on clinical trial results and has no correlation to the market, representing a high-risk investment in the medicine of the future.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Allogene Therapeutics
Shares of Allogene Therapeutics, a pioneer in allogeneic CAR-T cancer therapy, are extremely volatile. Weekly price movements depend entirely on clinical trial results and news about the progress of their "ready-to-use" cell therapy. The chart below illustrates how short-term scientific events shape biotech valuations.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
How unique is Allogene Therapeutics' performance in the biotech sector? This chart compares the weekly stock price movements of this allogeneic CAR-T therapy pioneer with the overall trend. This helps us understand whether its sharp movements are a unique reaction to news in this cutting-edge field or reflect the broader sentiment of the volatile sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T cancer therapy (ready-to-use). This chart shows how disconnected its weekly performance is from the market. Its stock price is driven by clinical trial news and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
ALLO - Market capitalization of the company Allogene Therapeutics
Allogene Therapeutics' market capitalization is a bet on its innovative platform for "off-the-shelf" CAR-T cancer therapy using cells from healthy donors. The company's valuation hinges on the success of its clinical trials. The chart vividly illustrates the enormous promise and risks associated with this revolution in cell therapy.
ALLO - Share of the company's market capitalization Allogene Therapeutics within the market segment - Oncology cell gene therapy
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T therapy, aiming to gain market share. Its capitalization is a bet that its "off-the-shelf" cell therapies from donors will make this revolutionary cancer therapy more accessible.
Market capitalization of the market segment - Oncology cell gene therapy
The chart below shows the combined market capitalization of biotech companies developing "off-the-shelf" (allogeneic) cell therapies. Allogene Therapeutics is one of the leaders in this revolutionary field. The dynamics in the chart reflect hopes for the creation of a more affordable and faster alternative to personalized CAR-T therapy.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's a visualization of the market value of a breakthrough in cancer treatment. Allogene Therapeutics' market capitalization is based on its "off-the-shelf" cell therapy from donors, not from patients themselves. The line shows how a scientific idea that could make treatment more accessible is generating a huge potential share of the global economy.
Book value capitalization of the company, segment and market as a whole
ALLO - Book value capitalization of the company Allogene Therapeutics
Allogene Therapeutics' book value is its research and production capital. The chart below reflects the valuation of its patents for its allogeneic CAR-T therapy platform and its manufacturing capacity. Growth in the pipeline reflects investments in the development of "off-the-shelf" cell therapies for cancer treatment, which are its main asset.
ALLO - Share of the company's book capitalization Allogene Therapeutics within the market segment - Oncology cell gene therapy
Allogene Therapeutics' tangible assets include its state-of-the-art manufacturing complex and R&D centers for creating ready-to-use CAR-T cell therapies. The chart shows its share of this capital-intensive and cutting-edge manufacturing infrastructure, which is key to the future of cancer treatment.
Market segment balance sheet capitalization - Oncology cell gene therapy
Below you can see the overall book value of the biotech sector. Against this backdrop, Allogene, as a pioneer in "off-the-shelf" CAR-T therapy, is capital-intensive. Unlike R&D companies, it builds its own large and complex factories to manufacture its cell products, which requires massive investments.
Book value of all companies included in the broad market index - GURU.Markets
Allogene Therapeutics is a pioneer in the development of "off-the-shelf" allogeneic CAR-T therapy, using cells harvested from healthy donors. The company's assets are not hospitals, but a scientific platform, patents, and manufacturing facilities. Their balance sheet represents the value of a "factory" for creating universal cell-based therapies to fight cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Allogene Therapeutics
Allogene's balance sheet is its massive cash reserves and scientific platform. A market capitalization close to this cash value shows that investors have almost completely written off its scientific "dreams" after a series of setbacks. The MvsBCap_Co chart here ≈ 1 represents the company's valuation as a "cash pit" with a small, free option for a miracle.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Allogene Therapeutics is a pioneer in the development of "off-the-shelf" (allogeneic) CAR-T cell therapy for cancer. Its value lies in its revolutionary scientific platform. The chart shows the enormous speculative premium the market places on its potential to create a more affordable and faster treatment than existing methods.
Market to book capitalization ratio for the market as a whole
Allogene Therapeutics is a biotech company developing allogeneic CAR-T (ready-to-use) therapy for cancer treatment. Unlike autologous therapy, its products can be manufactured in advance and for multiple patients. The company's value lies in its scientific platform. This chart illustrates why investors are willing to pay a premium for innovative approaches in oncology.
Debts of the company, segment and market as a whole
ALLO - Company debts Allogene Therapeutics
Allogene Therapeutics, a pioneer in allogeneic CAR-T therapy, is using debt to finance its revolutionary approach to cancer treatment. This chart shows how the company is raising massive capital for clinical trials of its "off-the-shelf" cell therapies. In this field, debt is a bet on creating a more affordable and faster alternative to personalized therapy.
Market segment debts - Oncology cell gene therapy
Allogene Therapeutics is a pioneer in the development of "off-the-shelf" (allogeneic) CAR-T cell therapy, which could make this powerful cancer treatment more accessible. This is one of the most advanced and capital-intensive areas in biotechnology. This chart shows how the company is funding its ambitious research and development efforts while in the clinical stage.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Allogene Therapeutics
Allogene Therapeutics is a pioneer in allogeneic cell therapy for cancer. This chart shows the company's reliance on external capital to fund breakthrough, but very expensive, research. For a biotech company at the forefront of science, debt is a risky bet on success. Failure in clinical trials could jeopardize the entire financial structure.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Allogene Therapeutics is a biotech company developing allogeneic CAR-T cancer therapy (using donor cells). This is a promising but capital-intensive approach. The chart shows how the company's debt load for R&D funding compares to the market capitalization and risks of the overall cell therapy sector.
Debt to book value of all companies in the market
Allogene Therapeutics (ALLO) is a biotech company developing allogeneic CAR-T cell therapy for cancer. This is a cutting-edge, yet capital-intensive, field. This chart shows the overall level of debt in the economy. It clearly demonstrates why biotech companies in the R&D stage use virtually no debt in their capital structure.
P/E of the company, segment and market as a whole
P/E - Allogene Therapeutics
For Allogene Therapeutics, a company developing "off-the-shelf" CAR-T cell therapies for cancer, this chart is a measure of faith in its scientific approach. There is no P/E ratio. The company's valuation is based on the potential of its technology to become a more affordable and rapid alternative to existing personalized cell therapies.
P/E of the market segment - Oncology cell gene therapy
This chart shows the average P/E valuation for biotech companies focused on cell therapy. For Allogene, a pioneer in off-the-shelf therapies, it serves as a backdrop. It reflects the overall level of investor confidence in this field, providing context for Allogene's valuation, which is a bet on its unique and potentially breakthrough scientific approach.
P/E of the market as a whole
Allogene Therapeutics is a biotech company developing allogeneic CAR-T (ready-to-use) therapy for cancer treatment. Unlike autologous therapy, their approach does not require the use of the patient's own cells. This risk appetite chart helps understand how investors are evaluating this new generation of cell therapy.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Allogene Therapeutics
Allogene Therapeutics is a biotech company developing "off-the-shelf" (allogeneic) CAR-T therapy for cancer treatment. This timeline reflects expectations for a revolution in cell therapy. Unlike personalized therapies, their approach promises more affordable treatment. Evaluation depends entirely on success in clinical trials.
%20P%2FE%20Allogene%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Allogene-Therapeutics&v=1772668339964 "Chart of the company's future (projected) P/E Allogene Therapeutics")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Allogene Therapeutics is a biotech company developing allogeneic CAR-T (ready-to-use) cancer therapy. This chart reflects the company's long-term profitability expectations compared to other biotechs. It shows how highly the market values their potential to revolutionize cell therapy by making it more accessible.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772668339988 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T cancer therapy using cells from healthy donors. The company's success depends on clinical breakthroughs. This market expectations chart reflects investor willingness to fund capital-intensive biotech research. Market optimism increases access to funding for such innovators.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772668340028 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Allogene Therapeutics
Allogene Therapeutics is a biotech company developing a "universal" CAR-T cell therapy for cancer treatment. Unlike existing methods, its drugs can be manufactured in advance and used for any patient. Its financial performance reflects the massive investment in this breakthrough technology.
Profit of companies in the market segment - Oncology cell gene therapy
Allogene Therapeutics is a pioneer in developing ready-to-use CAR-T cell therapies for cancer from donor cells. This technology has the potential to make treatment more accessible. The company is in the R&D phase. This chart reflects the cumulative investment in cell therapy—one of the most promising, yet capital-intensive, areas in biotechnology, shaping the future of oncology.
Overall market profit
Allogene Therapeutics is a biotech company developing allogeneic CAR-T therapy for cancer ("off-the-shelf" cell therapy). Its future depends entirely on the success of clinical trials. This is a high-risk, high-reward scenario that is unrelated to the macroeconomic trends reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Allogene Therapeutics
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T cancer therapy using cells from healthy donors. This timeline reflects analyst expectations, which are entirely dependent on the success of clinical trials. Advances in creating "ready-to-use" cell therapy could revolutionize cancer treatment and dramatically alter prognoses.
%20profit%20of%20the%20company%20Allogene%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Allogene-Therapeutics&v=1772668340253 "Graph of future (projected) profit of the company Allogene Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Allogene Therapeutics is a biotechnology company developing allogeneic CAR-T (CAR-T) therapy for cancer treatment. This chart shows the revenue forecast for the cell and gene therapy sector. It reflects expectations for breakthroughs in cancer treatment. This background is important for assessing the potential of Allogene's technology, which could make CAR-T therapy more accessible.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772668340375 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T cancer therapy (using donor cells). Like other biotech companies, its future depends on science and investment. The overall economic climate, illustrated here, influences investor risk appetite and the availability of capital to fund breakthrough, but very expensive, medical research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772668340464 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Allogene Therapeutics
Allogene Therapeutics is a clinical-stage biotech pioneering the development of "off-the-shelf" (allogeneic) CAR-T cell therapies for cancer. This chart shows how investors value its scientific platform, which could make cell therapy more accessible, pricing in its enormous future potential.
P/S market segment - Oncology cell gene therapy
Allogene Therapeutics is a biotech company pioneering the development of allogeneic CAR-T cell therapy for cancer treatment. Unlike autologous therapy, their approach uses cells from healthy donors to create ready-to-use drugs. This chart shows the average valuation in the sector, helping to understand the market premium for this potentially revolutionary technology.
P/S of the market as a whole
Allogene Therapeutics is a biotech company pioneering the development of allogeneic CAR-T cancer therapy. Unlike existing methods, their "off-the-shelf" cell products can be obtained from healthy donors, simplifying treatment. This market valuation chart helps understand the premium investors are paying for the biotech's potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Allogene Therapeutics
Allogene Therapeutics is a biotech company developing allogeneic CAR-T (ready-to-use) cancer therapy. Without revenue, it is valued based on future potential. This chart reflects investors' belief that its approach to cell therapy will be a breakthrough and generate billions in sales.
%20P%2FS%20Allogene%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Allogene-Therapeutics&v=1772668340635 "The graph of the company's future (projected) P/S Allogene Therapeutics")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T cell therapy (ready-to-use) for cancer treatment. This chart compares market expectations for its future revenue with other oncology companies. The valuation reflects investors' high expectations for its breakthrough platform, which could make cell therapy more accessible.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772668340650 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Allogene Therapeutics is a pioneer in the development of off-the-shelf (allogeneic) CAR-T cell therapies for cancer treatment. It is betting on a revolution in oncology. Market optimism, as reflected in this chart, is critical for the company, as it provides access to the massive investment needed to advance this complex technology through clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772668340663 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Allogene Therapeutics
Allogene Therapeutics is a biotech company developing off-the-shelf (allogeneic) CAR-T therapy for cancer treatment. Unlike existing methods, its approach utilizes cells from healthy donors. Currently in clinical trials, the company's revenue comes from partnerships. The chart reflects funding for this innovative oncology platform.
Sales of companies in the market segment - Oncology cell gene therapy
Allogene Therapeutics is a biotech company pioneering the development of allogeneic CAR-T cancer therapy. Unlike existing methods, its approach uses cells from healthy donors, potentially making the treatment more accessible. There is currently no revenue. This chart reflects the enormous potential and investor interest in cell therapy, which has the potential to transform cancer treatment.
Overall market sales
Allogene Therapeutics is a pioneer in the development of "off-the-shelf" (allogeneic) CAR-T cell therapies for cancer treatment. The company's prospects depend solely on the results of clinical trials. The connection to this timeline is indirect: the state of the economy affects the stock market and the availability of capital to fund expensive biotech research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Allogene Therapeutics
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T cancer therapy. Unlike existing methods, their approach uses donor cells, which could make the treatment more accessible. This graph reflects analysts' expectations for the success of clinical trials and the potential of this "ready-to-use" cell therapy in oncology.
%20sales%20of%20the%20company%20Allogene%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Allogene-Therapeutics&v=1772668340868 "Schedule of future (projected) sales of the company Allogene Therapeutics")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Allogene Therapeutics is a biotech company developing off-the-shelf (allogeneic) CAR-T therapy for cancer treatment. This chart shows the outlook for the cell therapy sector. It allows us to assess whether the company's approach, potentially cheaper and more accessible than existing CAR-T methods, could revolutionize cancer treatment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772668340878 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Allogene Therapeutics is a biotech company developing off-the-shelf (allogeneic) CAR-T therapy for cancer treatment. This chart, reflecting the investment climate in biotech, is critically important. Developing such an innovative platform requires significant investment, and Allogene's ability to attract capital depends directly on investors' confidence in the company's future success.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772668340886 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Allogene Therapeutics
Allogene Therapeutics is developing "off-the-shelf" (allogeneic) CAR-T cell therapies for cancer treatment. This cutting-edge biotechnology requires significant investment in research and clinical trials. This chart illustrates the current costs of developing a platform that could revolutionize oncology.
Market segment marginality - Oncology cell gene therapy
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T therapy. Unlike existing methods, their "off-the-shelf" cells can be used to treat multiple patients, significantly reducing costs and time. This graph reflects the scale of investment in this breakthrough platform, which has the potential to revolutionize cancer cell therapy.
Market marginality as a whole
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T therapy, which uses donor cells to create a "ready-to-use" cancer treatment. The overall profitability picture is irrelevant to them. Their value lies in the potential of their scientific platform. Success depends on demonstrating that their approach is safe and effective, which could revolutionize cell therapy.
Employees in the company, segment and market as a whole
Number of employees in the company Allogene Therapeutics
Allogene Therapeutics is a leader in the development of allogeneic CAR-T therapy, aiming to create "off-the-shelf" cancer treatments. This chart shows a large and growing team of scientists. This increase in staff is directly related to the massive investment in this complex technology, clinical trials, and the construction of manufacturing facilities.
Share of the company's employees Allogene Therapeutics within the market segment - Oncology cell gene therapy
Allogene Therapeutics is a leader in the development of allogeneic CAR-T therapy, which uses cells from healthy donors to treat cancer. This chart shows the percentage of leading scientists in this breakthrough field of cell therapy that the company attracts. It illustrates its ambition to make this powerful cancer treatment more accessible to patients.
Number of employees in the market segment - Oncology cell gene therapy
Allogene Therapeutics is a biotech company pioneering the development of "off-the-shelf" (allogeneic) CAR-T therapy for cancer treatment. This chart shows the growth of employment in the cell therapy sector. The increase in scientists reflects the race to create treatments that are more accessible than existing personalized CAR-T technologies.
Number of employees in the market as a whole
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T cell therapy for cancer. Unlike autologous therapy, their therapy uses cells from healthy donors, making treatment more accessible. This graph shows overall employment, and biotech companies like Allogene are at the forefront of science, creating jobs for highly qualified scientists and clinicians.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Allogene Therapeutics (ALLO)
Allogene Therapeutics, Inc. is a biotech company developing allogeneic CAR-T cancer therapy. Its valuation is based entirely on scientific potential. This chart demonstrates a model where intellectual capital dominates. A small team of scientists can create a platform worth billions of dollars, resulting in an extremely high valuation per employee.
%20of%20the%20company%20Allogene%20Therapeutics%20(ALLO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Allogene-Therapeutics-ALLO&v=1772668341407 "Chart of market capitalization per employee (in thousands of dollars) of the company Allogene Therapeutics (ALLO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T cell therapy (ready-to-use). For a biotech company with a revolutionary platform, this metric reflects investor expectations. The chart illustrates the enormous value the market places on each scientist working on a universal cancer cure.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772668341439 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T therapy, or "off-the-shelf" cell therapy for cancer treatment from healthy donors. This chart shows a very high market value per employee, reflecting the enormous potential of their scientific platform, which could make cell therapy more accessible.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772668341522 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Allogene Therapeutics (ALLO)
Allogene Therapeutics (ALLO) is a pioneer in the development of "allogeneic" CAR-T therapies (cancer treatment using cells from a healthy donor). This is cutting-edge R&D. This chart illustrates the high "cost" of these innovations: it measures the negative profit (R&D costs) per scientist striving to make cell therapy accessible and "ready to use."
%20Chart%20Allogene%20Therapeutics%20(ALLO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Allogene-Therapeutics-ALLO&v=1772668341639 "Company Profit Per Employee (in thousands of dollars) Chart Allogene Therapeutics (ALLO)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T therapy. Their goal is to create ready-to-use cell therapy from healthy donor cells. This chart demonstrates the benchmark for biotech staff efficiency and is important for assessing how effectively Allogene's scientific team is using its capital to create this breakthrough platform.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772668341696 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Allogene Therapeutics is a biotech company working on the development of "allogeneic" CAR-T cancer therapy. Unlike existing (autologous) methods, their goal is to create universal, "ready-to-use" cells from healthy donors. This is the Holy Grail of cell therapy. The chart shows the enormous R&D costs per scientist in the quest to achieve this scientific breakthrough.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772668341722 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Allogene Therapeutics (ALLO)
Allogene Therapeutics is a biotech company developing allogeneic (donor-derived) CAR-T therapy for cancer treatment. This chart reflects its clinical status. No revenue per employee is standard for companies whose breakthrough technology is still in development and has not yet reached the market. The entire team is focused on research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Allogene-Therapeutics-ALLO&v=1772668341747 "Sales chart per company employee Allogene Therapeutics (ALLO)")
Sales per employee in the market segment - Oncology cell gene therapy
Allogene Therapeutics (ALLO) is a biotech company developing "allogeneic" CAR-T therapy (using cells from healthy donors, not the patient) to treat cancer. This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their advanced off-the-shelf R&D platform.
Sales per employee for the market as a whole
Allogene Therapeutics is a pioneer in allogeneic CAR-T therapy. They aim to create "off-the-shelf" cell therapies for cancer treatment from healthy donors. They are a clinical-stage R&D company. This graph is close to zero. The company has no revenue, but it has a large staff of scientists working on this breakthrough technology. This indicator reflects net investment in research.
Short shares by company, segment and market as a whole
Shares shorted by company Allogene Therapeutics (ALLO)
Allogene Therapeutics is a biotech company developing allogeneic CAR-T therapy (using donor cells) for cancer treatment. This chart shows bearish bets. The shorts are driven by high risks: the technology is highly complex, and serious safety issues have emerged during trials, casting doubt on the future of their platform.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Allogene-Therapeutics-ALLO&v=1772668341825 "Short Shares Chart for the Company Allogene Therapeutics (ALLO)")
Shares shorted by market segment - Oncology cell gene therapy
Allogene Therapeutics (ALLO) is a clinical-stage biotech company developing "allogeneic" CAR-T therapy (using donor cells) for the treatment of cancer. This chart is a barometer of sentiment across the entire biotech industry. If investors are shorting the sector, they don't believe in the success of this complex technology. For ALLO, this signals a dry spell of venture capital needed for expensive trials.
Shares shorted by the overall market
Allogene Therapeutics (ALLO) is a clinical-stage biotech developing a "off-the-shelf" (allogeneic) CAR-T cancer therapy. This is cutting-edge, but speculative, science. This chart of general pessimism shows when investors are fleeing risky assets. ALLO shares, dependent on the success of the trials, are the first to fall victim to the sell-off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Allogene Therapeutics (ALLO)
Allogene is a pioneer in allogeneic CAR-T therapy (using cells from a donor, not a patient). This is a breakthrough, but extremely risky, oncology treatment. This chart measures the level of hype. It shows when data euphoria (overbought) or fears (oversold) reach extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Allogene-Therapeutics-ALLO&v=1772668341884 "RSI 14 indicator chart for the company's stock Allogene Therapeutics (ALLO)")
RSI 14 Market Segment - Oncology cell gene therapy
Allogene Therapeutics is a biotech company pioneering the development of "allogeneic" CAR-T therapy. Unlike autologous therapy, their therapy utilizes T cells from healthy donors ("ready-to-use"). This chart measures the collective excitement in the cell therapy sector. It helps determine whether the entire segment is oversold.
RSI 14 for the overall market
Allogene Therapeutics, a biotech company, depends on this schedule. To fund expensive clinical trials, it requires a constant influx of capital. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like ALLO are forced to struggle to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ALLO (Allogene Therapeutics)
Allogene Therapeutics is a biotech company developing allogeneic CAR-T cancer therapies. These are off-the-shelf cell therapies from healthy donors. This chart shows the average analyst forecast. Their targets are based on clinical data demonstrating the efficacy and safety of this approach compared to the autologous approach.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ALLO-Allogene-Therapeutics&v=1772668341983 "A chart showing analyst consensus forecasts for the expected stock price. ALLO (Allogene Therapeutics)")
The difference between the consensus estimate and the actual stock price ALLO (Allogene Therapeutics)
Allogene (ALLO) is a pioneer in allogeneic CAR-T therapy. They are trying to create universal (ready-made, donor-derived) T cells for cancer treatment, which is cheaper than personalized ones. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the enormous potential analysts see in their off-the-shelf cell therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ALLO-Allogene-Therapeutics&v=1772668341990 "A chart showing the difference between the consensus forecast and the actual stock price. ALLO (Allogene Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Allogene Therapeutics is a pioneer in the field of "allogeneic" CAR-T therapy. Unlike "autologous" therapy (using patient-derived cells), they create "universal" cancer-killing cells from healthy donors. This chart shows general expectations for the oncology sector, reflecting whether experts believe in this "off-the-shelf" cell therapy.
Analysts' consensus forecast for the overall market share price
Allogene Therapeutics is a pioneer in the development of allogeneic CAR-T therapy (using ready-made donor cells) for cancer treatment. This sector has the highest risk and revolutionary potential. This chart shows the overall risk appetite. For Allogene, whose value is based on future breakthroughs, overall market optimism (a rising chart) is absolutely necessary to fund expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Allogene Therapeutics
Allogene Therapeutics is a pioneer in universal cell therapy. They develop allogeneic (universal, off-the-shelf) CAR-T cells from healthy donors that can be given to any patient, unlike autologous (personalized) therapies. This graph is a clear indicator of faith in their R&D. It reflects their ability to address the most complex immunological challenges (rejection) of this technology.
AKIMA Market Segment Index - Oncology cell gene therapy
Allogene Therapeutics is a pioneer in allogeneic cell therapy (CAR-T), which uses cells from healthy donors to fight cancer. This chart shows the average index for the gene therapy sector. It provides investors with a benchmark for how Allogene's overall performance, a company with a revolutionary but risky technology, compares to the sector average.
The AKIM Index for the overall market
Allogene Therapeutics is a biotech company leading the development of allogeneic (ready-to-use, "out-of-the-box") CAR-T therapies for cancer treatment. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this cutting-edge scientific platform compares to the overall economic trends impacting the cell therapy sector.
